{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:01:42Z","timestamp":1782331302007,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T00:00:00Z","timestamp":1317340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1038\/eye.2011.239","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T09:47:48Z","timestamp":1317376068000},"page":"80-87","source":"Crossref","is-referenced-by-count":18,"title":["Twenty-four hour efficacy with the dorzolamide\/timolol-fixed combination compared with the brimonidine\/timolol-fixed combination in primary open-angle glaucoma"],"prefix":"10.1038","volume":"26","author":[{"given":"A G P","family":"Konstas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D B","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D G","family":"Mikropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N K","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-B","family":"Haidich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,30]]},"reference":[{"key":"BFeye2011239_CR1","first-page":"565","volume-title":"Glaucoma","author":"AGP Konstas","year":"2009","unstructured":"Konstas AGP, Mikropoulos D, Stewart WC . Fixed combination therapy in glaucoma. In: Shaarawy T, Hitchings R, Sherwood M, Crowston J (eds). Glaucoma. Elsevier, USA, 2009, pp 565\u201375."},{"key":"BFeye2011239_CR2","first-page":"935","volume":"82","author":"J Connor","year":"2004","unstructured":"Connor J, Rafter N, Rodgers A . Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004; 82: 935\u2013939.","journal-title":"Bull World Health Organ"},{"key":"BFeye2011239_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","volume":"120","author":"S Bangalore","year":"2007","unstructured":"Bangalore S, Kamalakkannan G, Parkar S, Messerli FH . Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713\u2013719.","journal-title":"Am J Med"},{"key":"BFeye2011239_CR4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/j.1368-5031.2005.00704.x","volume":"59","author":"AA Petrilla","year":"2005","unstructured":"Petrilla AA, Benner JS, Battleman DS, Tierce JC, Hazard EH . Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract 2005; 59: 1441\u20131451.","journal-title":"Int J Clin Pract"},{"key":"BFeye2011239_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Olthoff CM, Schouten JSAG, Borne van der BW, Webers CA . Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. Ophthalmology 2005; 112: 953\u2013961.","journal-title":"Ophthalmology"},{"key":"BFeye2011239_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/01.icu.0000156139.05323.26","volume":"16","author":"GF Schwartz","year":"2005","unstructured":"Schwartz GF . Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005; 16: 114\u2013121.","journal-title":"Curr Opin Ophthalmol"},{"key":"BFeye2011239_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00003495-200262030-00003","volume":"62","author":"DA Sica","year":"2002","unstructured":"Sica DA . Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62: 443\u2013462.","journal-title":"Drugs"},{"key":"BFeye2011239_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0149-2918(02)85047-0","volume":"24","author":"C Melikian","year":"2002","unstructured":"Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E . Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460\u2013467.","journal-title":"Clin Ther"},{"key":"BFeye2011239_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/bjo.2008.139329","volume":"92","author":"JA Cox","year":"2008","unstructured":"Cox JA, Mollan SP, Bankart J, Robinson R . Efficacy of antiglaucoma fixed combination therapy vs unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol 2008; 92: 729\u2013734.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2011239_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ophtha.2005.10.034","volume":"113","author":"B Sleath","year":"2006","unstructured":"Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B . Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006; 113: 431\u2013436.","journal-title":"Ophthalmology"},{"key":"BFeye2011239_CR11","unstructured":"European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd ed. DOGMA S.r.l., Savona, 2008."},{"key":"BFeye2011239_CR12","first-page":"1","volume":"4","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ . Considerations in glaucoma therapy: fixed combinations vs their component medications. Clin Ophthalmol 2010; 4: 1\u20139.","journal-title":"Clin Ophthalmol"},{"key":"BFeye2011239_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1517\/14656561003667540","volume":"11","author":"MR Razeghinejad","year":"2010","unstructured":"Razeghinejad MR, Sawchyn AK, Katz LJ . Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother 2010; 11: 959\u2013968.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"BFeye2011239_CR14","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.survophthal.2008.08.011","volume":"53","author":"R Tabet","year":"2008","unstructured":"Tabet R, Stewart WC, Feldman R, Konstas AGP . A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol 2008; 53 (Suppl 1): S85\u2013S92.","journal-title":"Surv Ophthalmol"},{"key":"BFeye2011239_CR15","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1136\/bjo.82.11.1249","volume":"82","author":"J Hutzelmann","year":"1998","unstructured":"Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E . Comparison of the safety and efficacy of the fixed combination of dorzolamide\/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. Br J Ophthalmol 1998; 82: 1249\u20131253.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2011239_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/112067210501500508","volume":"15","author":"FJ Goni","year":"2005","unstructured":"Goni FJ, Brimonidine\/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005; 15: 581\u2013590.","journal-title":"Eur J Ophthalmol"},{"key":"BFeye2011239_CR17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.eye.6702906","volume":"22","author":"AGP Konstas","year":"2008","unstructured":"Konstas AGP, Katsimpris IE, Kaltsos K, Georgiadou I, Kordelou A, Nelson LA et al. Twenty-four-hour efficacy of the brimonidine\/timolol fixed combination vs therapy with the unfixed components. Eye 2008; 22: 1391\u20131397.","journal-title":"Eye"},{"key":"BFeye2011239_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/jop.2005.21.337","volume":"21","author":"ER Craven","year":"2005","unstructured":"Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R et al. Brimonidine and timolol fixed-combination therapy vs monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005; 21: 337\u2013348.","journal-title":"J Ocul Pharmacol Ther"},{"key":"BFeye2011239_CR19","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","volume":"124","author":"MB Sherwood","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006; 124: 1230\u20131238.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2011239_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ophtha.2007.10.004","volume":"115","author":"WC Stewart","year":"2008","unstructured":"Stewart WC, Konstas AGP, Nelson LA, Kruft B . Meta-analysis of 24-hour intraocular pressure studies evaluating efficacy of glaucoma medicines. Ophthalmology 2008; 115: 1117\u20131122.","journal-title":"Ophthalmology"},{"key":"BFeye2011239_CR21","first-page":"10","volume":"106","author":"JE Boyle","year":"1999","unstructured":"Boyle JE, Ghosh K, Gieser DK, Adamsons IA . A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 1999; 106: 10\u201316.","journal-title":"Ophthalmology"},{"key":"BFeye2011239_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1046\/j.1600-0420.2004.0205.x","volume":"82","author":"RD Fechtner","year":"2004","unstructured":"Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA . Efficacy and tolerability of the dorzolamide 2%\/timolol 0.5% combination (Cosopt) vs 0.005% (Xalatan) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004; 82: 42\u201348.","journal-title":"Acta Ophthalmol Scand"},{"key":"BFeye2011239_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ophtha.2003.05.019","volume":"111","author":"DH Shin","year":"2004","unstructured":"Shin DH, Feldman RM, Sheu WP . Efficacy and safety of the fixed combinations latanoprost\/timolol vs dorzolamide\/timolol in patients with elevated intraocular pressure. Ophthalmology 2004; 111: 276\u2013282.","journal-title":"Ophthalmology"},{"key":"BFeye2011239_CR24","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/eye.2009.307","volume":"24","author":"S Miglior","year":"2010","unstructured":"Miglior S, Grunden JW, Kwok K . Efficacy and safety of fixed combinations of latanoprost\/timolol and dorzolamide\/timolol in open-angle glaucoma or ocular hypertension. Eye 2010; 24: 1234\u20131242.","journal-title":"Eye"},{"key":"BFeye2011239_CR25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0161-6420(03)00404-4","volume":"110","author":"AGP Konstas","year":"2003","unstructured":"Konstas AGP, Papapanos P, Tersis I, Houliara D, Stewart WC . Twenty-four- hour diurnal curve comparison of commercially available latanoprost 0.005% vs timolol and dorzolamide fixed combination. Ophthalmology 2003; 110: 1357\u20131360.","journal-title":"Ophthalmology"},{"key":"BFeye2011239_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ophtha.2007.03.007","volume":"115","author":"AGP Konstas","year":"2008","unstructured":"Konstas AGP, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC . Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide\/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology 2008; 115: 99\u2013103.","journal-title":"Ophthalmology"},{"key":"BFeye2011239_CR27","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1167\/iovs.08-1744","volume":"49","author":"L Quaranta","year":"2008","unstructured":"Quaranta L, Miglior S, Floriani I, Pizzolante T, Konstas AGP . Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. Invest Ophthalmol Vis Sci 2008; 49: 4226\u20134231.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011239_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1185\/030079907X178694","volume":"23","author":"ES Arcieri","year":"2007","unstructured":"Arcieri ES, Arcieri RS, Pereira AC, Andreo EG, Finotti IG, S\u00e1 Filho WF . Comparing the fixed combination brimonidine-timolol vs fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin 2007; 23: 683\u2013689.","journal-title":"Curr Med Res Opin"},{"key":"BFeye2011239_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/IJG.0b013e318168f008","volume":"17","author":"M Hatanaka","year":"2008","unstructured":"Hatanaka M, Grigera DE, Barbosa WL, Jordao M, Susanna R . An eight-week multicentric, randomized, interventional, open-label, Phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%\/brimonidine tartrate 0.2% vs fixed combination of timolol maleate 0.5%\/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma 2008; 17: 674\u2013679.","journal-title":"J Glaucoma"},{"key":"BFeye2011239_CR30","unstructured":"Konstas AGP, Quaranta L, Miglior S, Mikropoulos DG, Bozkurt B . Twenty-four hour intraocular pressure monitoring in glaucoma. Expert Rev Ophthalmol 2011 (in press)."},{"key":"BFeye2011239_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/biomet\/73.3.751","volume":"73","author":"RJ Simes","year":"1986","unstructured":"Simes RJ . An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986; 73: 751\u2013754.","journal-title":"Biometrika"},{"key":"BFeye2011239_CR32","first-page":"63","volume-title":"Nonparametric Statistics for the Behavioral Sciences","author":"S Siegel","year":"1956","unstructured":"Siegel S. . Nonparametric Statistics for the Behavioral Sciences. McGraw Hill: New York, 1956, pp 63\u201367."},{"key":"BFeye2011239_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0002-9394(01)00834-0","volume":"131","author":"AGP Konstas","year":"2001","unstructured":"Konstas AGP, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos N . Brimonidine 0.2% given two or three times daily vs timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol 2001; 131: 729\u2013733.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2011239_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archopht.121.4.453","volume":"121","author":"N Orzalesi","year":"2003","unstructured":"Orzalesi N, Rossetti L, Bottoli A . The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003; 121: 453\u2013457.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2011239_CR35","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1167\/iovs.05-1253","volume":"47","author":"L Quaranta","year":"2006","unstructured":"Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante D, Musig A et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006; 47: 2917\u20132923.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011239_CR36","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ophtha.2010.03.026","volume":"117","author":"JHK Liu","year":"2010","unstructured":"Liu JHK, Medeiros FA, Slight JR, Weinreb RN . Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 2010; 117: 2075\u20132079.","journal-title":"Ophthalmology"},{"key":"BFeye2011239_CR37","first-page":"2566","volume":"41","author":"N Orzalesi","year":"2000","unstructured":"Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A . Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000; 41: 2566\u20132573.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011239_CR38","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1185\/03007990902994041","volume":"25","author":"DR Nixon","year":"2009","unstructured":"Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA . Three-month, randomized, parallel-group comparison of brimonidine-timolol vs dorzolamide-timolol fixed combination therapy. Curr Med Res Opin 2009; 25: 1645\u20131653.","journal-title":"Curr Med Res Opin"},{"key":"BFeye2011239_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000048296","volume":"216","author":"N Yuksel","year":"2002","unstructured":"Yuksel N, Karbas L, Altintas O, Yildrim Y, Caglar Y . A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure. Ophthalmologica 2002; 216: 45\u201349.","journal-title":"Ophthalmologica"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2011239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2011239","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2011239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:14:03Z","timestamp":1684430043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2011239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,30]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["BFeye2011239"],"URL":"https:\/\/doi.org\/10.1038\/eye.2011.239","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,30]]}}}